the military potential of 20 out of 30 nato countries is pretty depleted due to the help to ukraine, journalists found out about this, the new york times, there are already problems with weapons, for example, poland and the baltic states have another problem at the beginning of the year, the stocks of most members of the alliance were only half of the normative ones. and now this gap is even higher to liquidate with its almost impossible edition summarize since february. it is necessary to supply weapons to ukraine for almost $ 40 billion , which is equal to the annual defense budget of france. a popular american tv presenter called

president of ukraine a greedy dictator in his program. tucker carlson showed several videos in zelensky in everyone here asking for huge amounts of money for the war, the presenter emphasized that more than $ 90 billion has already been allocated to kiev, but zelensky is still not enough and malaya have you ever seen him, who is he ? why we are obliged to help him in reality, he is a corrupt ukrainian dictator demanding money from us, but he has enough impudence when he is already silent mig-31 fighters protect the sky in the special zone military operation. here are enemy helicopters and planes. footage of combat work showed the ministry of defense crews hitting air targets, guided missiles of the class, air to air and cover our troops perform patrols in designated areas, detecting the enemy strike. we carry out combat missions in the air to

cover troops and objects in the area of ​​​​the line of contact from an air attack and air reconnaissance of the enemy, we carry out the task together with ground points and air when air targets are detected, control points are carried out, we capture, identify, and after confirming the data and parameters of the targets, we use guided missiles of various classes of air against the enemy. in russia, for the first time, they began to produce protein from peas; the potential is huge; plans to use it as an alternative to meat and milk. taras kucherenko visited the opening of production. 2 years from idea to implementation, pea protein mini-factory is in demand from day one five manufacturers have already ordered raw materials for their products. and this, despite the fact that the project is a pilot, where the main task is to run in with

technology from 100 kg of pea flour, 20 kg of protein isolate is obtained as close as possible to the animal, but much cheaper, it can be used in the manufacture of sports nutrition ice cream of local products and drinks, a mini-factory with a capacity of 30 tons of protein per year was created within the walls of the uralchem ​​innovation center, skolkovo, 300 million rubles were invested in the creation of the plant. another 200 million allocated for the study was supported by the state. since the nineteenth year we have provided support for more than half a billion rubles for developments in this industry. and in the next two years we also plan to support import substitution. production that will be associated with the release of e various kinds of acids protein from peas is produced by only a few dozen enterprises in the world. how to make a quality product this secret, which each company carefully keeps, the final result is influenced by the variety of culture and

even what kind of water is used russian scientists have created their own technology using this technology. we can change the consumer properties of peas. e, changing them for different market segments, for example, e. speaking of drinks. here you need increased solubility, emulsifying ability plus. uh, flavors are reduced by introducing an enzyme that, let's say, trims the molecule, breaking them into small particles allows you to increase them. e. these are the properties of russia in second place in terms of production and export. last year, domestic agricultural producers supplied more than 1 million tons of dried peas to foreign markets. cost almost 400 million dollars, but protein isolate from peas had to be imported. we have plans for the construction of large-capacity

production. pea isolate, since at the moment pea isolate is not produced in the russian federation, but is partially imported from abroad. a, but nevertheless, we are aimed at completely covering the needs of the russian market for this product, as well as exporting to asian countries. selected, but it will be a number of agricultural producers once andrey kucherenko stanislav kurashev lead. in the first half of the year alone, the ministry of health issued approximately 400 permits for conducting clinical tests, almost a third more than in the same period in 2021. at the same time, western companies are closing part of the program, explaining this with logistics difficulties. here the share of russian is growing, where they are increasing the development of innovative drugs. watch the special report of the romanova molyte

company suspended clinical trials in in russia, what does this mean for the drug market for patient doctors? today? this is absolutely not a panic situation. so we have, firstly , accepted, as it were, uh, well, i don’t want to name it. this is an answer by numbers, but measures that, if necessary, will make it possible to obtain virtually any drug that is circulating somewhere on the world market in the future. some patients who are clearly in the study, but the drug helped and for them e access to a clinical study, early access to new innovative drugs. all in all country scale. this is probably not so, and that is, no one will notice such developments russian pharmaceutical companies are building up in august, we received permission to conduct a clinical study in spinal muscular therapy, where children under 8 months old will also be actively

implementing a program for measures of blastoma also younger patients. what original proprietary innovative research is being carried out right now is this a new target on the market today, and there are no drugs for this target, therefore, the molecule is unique, and we are planning this development, and to bring it out not only in russia but also to the world. at the world's largest gastrointestinal tumor symposium this summer in san francisco, the attention of many scientists was riveted on a tiny vial in a bottle of alphabet, the world's first targeted drug that works specifically against specific parts of cells in stomach tumors. solutions were developed by two leading oncologists from

russia, professor sergeyan and oncologist timofeev, scientists 6 years selected molecules until they received this exclusively russian development, and in the historical inhibitor of fibroblast growth receptors. behind these pseudo-scientific words, the essence of the discovery is to hit right on target, when the patient is no longer helping in such drugs in the world . we found that this target is expressed on stomach cancer cells and on cancer and ovarian cells, which are very common in russia, so the task was to come up with a drug that blocks this target this development lies in the fact that the drug binds to certain centers. in this recipe and changing it, the change of this receptor leads to the fact that the tumor cell of the stomach of stomach cancer is not activated and the tumor and metastases die of their startup, with the support of the fund. skolkov, conducted preclinical studies and the first phase is already on people alphabetically. introduced 21 patients

from russia, all gastric cancer with multiple metastases of chemotherapy, non-standard drugs. they didn’t help anymore, then someone was seriously ill 368% we achieved control over the disease, their tumor has ceased to develop these data, oncologists presented at a congress in the united states, their report was chosen from the three most interesting for a special discussion. another patient. six lines of therapy received the body stuffed with metastases. after 2 months of the appointment of the alphabet. itself did not begin to shrink enough. here, in particular, by 24%, one large by 7%, and most importantly, this patient, uh, has been living since may 2021 , has shown himself to be not very taxicious ahead, the second phase and follow-up already at 150%. alofanib has been shown to work in patients who have already exhausted standard therapy. that is, essentially. these

patients are candidates for hospice. the first results have allowed e, to initiate a phase ii study, where the alphabet will already be studied in previously untreated patients who have not received e, drug treatment. this is also stomach cancer, the second indication is ovarian cancer, for which there are also very few drugs and the small revolution, in this case for this tumor we decided to try use the alphabet and learn it in patients , too, who can no longer receive standard care. the russian company pharm - this is its production and laboratory in the moscow technopark acquired a license for alafanib. and already, together with the developers of the drug, it will conduct the second phase of studying research in oncology - this is mainly the study of foreign drugs, and this year, for obvious reasons, there are fewer and fewer of them, and in this regard, we, as a domestic company, are trying to maintain the level . a and uh

we take more and more innovative developments into our portfolio. this is an innovative molecule, and one of the first in the class, and we have very high hopes for its development and release. including in some foreign countries, the results of the first phase, they were also greatly inspired by the way the alphabet purposefully twists the receptor for tumor cells, the absence of strong side effects and the main thing, how it helps to prolong life and with the center in the city of omsk and the patient received, a received, in my opinion, 14 courses of chemotherapy, a to a. the appointment of lafonibo and uh, the duration of therapy with this particular drug was 18 months. this is a colossal period, that is, during this period, the patient showed a positive trend. in the second phase, specialists will continue to study the mechanisms of this drug. in the second phase, we already choose more specific doses based on the data of the first and e, carry out a preliminary assessment of the effectiveness. second phase.

yes, this is probably the most, but the key moment when we can understand that the drug is real works. and we are in the clinical research department of the logical science center. every year there are about 30 clinical trials of various drugs that are studied in patients with various types of endocrinopathy. this is the holy of holies of our department , a room for storing biological samples, which we receive as part of a study today at the leading federal endocrinological center in russia, about 200 volunteers, those who agreed to test new drugs on themselves, when all are on drips, these are usually very early phases of the study and most often healthy . volunteers and when it comes to patients and real patients who participate in studies this is, of course, an individual approach. russian and more often international studies have always taken place here, from 20 to 40 programs per

year, all studies that have been started, where patients have been included and their treatment continues, continue. probably since march or since april . in almost all new international studies, a set has been established. first it there were logistical problems, and then it was just decided to stop the recruitment in the center , they always tested innovative drugs and bio analogues of russian production, including new types of insulin. this sugar is 8.2, how good is it now. how much time has passed after eating. an hour and a half hour and a half, this is a very good first insulin injection in the world was made exactly 100 years ago in russia today about five million people with confirmed diabetes. while there is improvement in favor. that's it technical means of managing diabetes, which facilitate this management. at the same time, it allows to achieve such a level of glucose so close to normal that life expectancy is

not limited today, and complications do not develop at all. alexander lagutin was diagnosed with type 1 diabetes a few years ago , he participated in all possible clinical trials in the center of endocrinology and russian and imported drugs. when, for example, these daily studies were. i campaigned online. well, people with diabetes of the first, type, well, guys, of course, because there only men could participate and a rather large percentage of people who came read, informed consent and understood that they did not want, that they were afraid of health. yeah well, because it's not a resort, actually, uh, lie down. uh, a day or even more under droppers, when every 5 minutes they take blood from a vienna for myself, i decided to participate. this is an opportunity to get insulin someday, which you need to inject several times a day.

day, and for example, once a week, and someday in the future become. you can be one of the first who will even be cured. the hope remains that some absolute cure will be found for this disease. even though yes, in principle, i would say that i live life to the fullest. i don’t limit myself to anything, of course, i still remember my life when i didn’t have to count grams of carbohydrates. uh, in food and think about what's high or low or my sugar. yes, at the moment, perhaps the departure of many western studies from russian country scale nobody. and not because of this deadly disease, but such a withdrawal from the market will affect primarily patients suffering from some rare diseases or patients with oncological diseases, and who today have a very large choice of therapy, but for a doctor. if it's experience, it's again early access to new drugs. this is participation in international cooperation. so i don’t think that the

lack of research cuts us off for years from those drugs that the park companies want register in russia well, it's getting more complicated, we're still sending samples to western labs, and we're still running clinical trials that were four until february. and there are russian studies that will be processed in russia. in the first six months of 2022, the ministry of health issued 425 permits for clinical trials, which is almost 30% more than in the same period 1021 noticeably less in the list of international projects. but there are much more local trends for the redistribution of the research market the total number of studies for the first half of this year, and even more than for the first half of last year, or an average of statistics for 17 and 21 years. we are now talking about the statistics published by the association of clinical

trial organizers, but in the second quarter, the number of international clinical trials decreases, the number of local trials increases. the number of russian biovalence studies is increasing. eh, that is more relative the share of russian trials increased the share relative to international ones decreased in russia, foreign pharmaceutical companies. often, the last phases of research are carried out. they are already evaluating effective dosages side effects and almost always these are drugs for the most dangerous diseases. what clinical research means for the patient we understand that these are often breakthrough innovative drugs in areas such as oncology and for patients. enrolling in clinical research means sometimes saving a life the association of russian patients has already turned to western pharmaceutical companies. to return the study to the country, that is, you know this in some way for camouflage, but the refusal in the future to supply

life-saving drugs from drugs to our country, so we read here the interests and rights of patients is very cool. uh, they are violated, of course , the russian formalization industry is moving forward and there is, uh, a whole bunch of companies that work at the highest international level, but we must understand that everything, and all niches are just physically especially in a short time , foreign companies will not be able to close, they stopped recruiting russian ones. centov, explaining the suspension of the problem of logistics in order for the study to be validly recognized and its results not questioned, there are certain conditions. that's why the conditions of biomaterials. in the case of any checks and audits, they must be delivered within there in various ways from 24 to 48 hours to the central laboratory. unfortunately, on the territory of the russian federation, the central laboratory these events did not occur. the more we talk to the companies, the more they say they would love to

come back here. uh, either it will be open. e, the central laboratory on the territory of the russian federation, where we, respectively, will be able to withstand these guarantees, or the borders will be opened to russian standards, if at least one medical center did not participate in the studies. in russia, the drug cannot receive state registration and is legally sold. arfan, that is, extremely rare diseases, sechenov university spoke out that we will lose 300 promising drugs there in the near future, which could come to us and i do not agree with this, but apparently colleagues do not know our regulators very well, it will be able to get in, but this is not within the framework of multicenter studies, but if any company wants to register this drug in the russian federation, then it comes here and conducts only in the russian federation without including foreign countries. uh, pre-registration studies what's in there

russians will not participate. e in the study. well, it's in the research phase. they get this drug, they get it for free. well, this is quite small, like a hill, as a rule, out of the total number of cases, this does not absolutely mean that the drug will not come here. or vice versa, if the study. it was carried out here, then 100% that the drug will come here. dryness appeared in the organs of the eye, the nose in the mouth, the skin was very dry, and i had a problem in my eyes with vision, but no matter how my vision was focused, i worked at an idle institute, and i suddenly stopped. to work as before i was diagnosed. in general, it's enough. soon almost immediately. well, as far as i'm aware,

this disease is quite a rare autoimmune rheumatological disease and therefore drugs that directly treat exactly uh. this disease is not his, viz. eh, the ones that soften. uh, symptoms at this center that specializes in clinical research on innovative drugs. she got into a program testing a new russian cure for her illness that used to be symptom mitigation diseases. and now it’s precisely the disease, my syndromes that i’ve been noticing lately that it ’s gone, the rest of the symptoms also go away easier, so i see what i see to the benefit. that's exactly the

treatment. e, with a frequency of 2 weeks, er, i, er, i come to the clinic, er, a mandatory examination is carried out, the study is necessary at a given time and an injection is given, and the next 2 weeks. i have already come to such a moment that now i will leave myself hmm at home these injections all the drugs are given to me in my hands. she has been in the program for 2 years, this is not an opportunity not only to help scientists, but also to get quick access to treatment and undergo free examinations. i hope you get this medicine for a long time while the process is going on. uh, if research. and then, if it passes, this is a test with positive results, it goes on sale, then i can also get it , so i hope that we will help and my

positive results will help in bringing this drug to the market. i will take him clinic was created under the project of prevention and alzheimer's disease volunteers received drugs and were followed up for 5 years. today, there are researches in various areas of neurology, a lot of neurodegenerative diseases. uh, we were participating in clinical trials, and in this cardiology, we had a number of protocols for prevention, a dyslipidemia and cardiovascular complications. and we work in psychiatry, including in child psychiatry , recruiting new western studies. they stopped here, but at the same time, the tests already begun are continuing and, as the companies promise, they will be brought to the end, when hmm began to stop. and new

studies in russia and then current studies, well, at least in our center they all continued part of the analyzes. we are now sending to russian laboratories. these are invitro and helix and since we have to assess rather quickly, yes, safety for the patient, therefore, well, pharmaceutical companies, including global ones, and a number of them have made a decision, yes, and we are now working with russian laboratories. the same time those samples that require an a grade in the central laboratories. they continue to arrive at the central laboratory, despite any difficulties. petersburg pharmaceutical company biocad is known for its innovative developments. today, there are more and more studies of russian and breakthrough drugs and the number of ongoing clinical trials. we have

increased if last year there were 23 active programs, already in the twenty-second of them there are 37 and we plan to increase the number of clinical trials conducted simultaneously. drugs developed in russia, including for the treatment of melanoma and other diseases, in august we received permission to conduct a clinical trial in spinal muscular therapy, where children under 8 months old will participate , a program is also being actively implemented in neuroplastomy, also in younger patients, and it is interesting the research is from our original and the days are like no other drugs for the treatment of diseases. ankylosing spondylitis, this is called spondyloarthritis in a different way, and now the enrollment in the second phase is already being completed clinical research. at first it was the usual pain in the back, then the injections of the blockade no longer helped victor's vomer, as is most often the

case with ankylosing sponditis. she was diagnosed with ankylosing spondylitis at a young age, drugs bound by mobility. the only thing that is improved and the disease is amenable to full radiation is only stopped. now he is in remission and undergoes regular examinations. at the institute of lymphology in novosibirsk, exactly. here more than 20 years deal with the problems of rheumatology disease. ankylosing spondylitis causing fusion of the vertebrae has been successfully treated for all these years with genetic engineering preparations, but they are expensive and require special storage . in year. this is a serious burden on the budget. so here they thought about an alternative drug. bechterew's disease is extremely widespread rheumatic disease is considered to be that approximately 0.2.06% of the world's population suffers from this disease. this

colossal number. that average patient gets sick. about 20 years old, about 10 years old, the disease manifests itself in the fact that his back hurts in the morning. he doesn't pay attention to it. he believes that everyone will consider him some kind of simulator for agrants. that's only when he can no longer get up save or he starts to think about himself now go to clinical trials the drug will be based on optomers of small molecules that bind to target molecules and beat the targets of the optomeres. this synthesized artificial chemical synthesized. and short fragments of nucleic acids that are able to specifically bind a strictly defined target molecule, in our case such a molecule is mifen - this is interleukin, 17, which, uh, triggers inflammation in spondylitis . our task is to bind this molecule with the help of an optomer and place it to give a signal for

inflammation of the beta laboratory, the molecule synthesizes. so far, research is being done on specially bred mice. synthesized molecules showed that it is not toxic to laboratory animals and showed that in mufei, in whom we specifically induced, a spondyloarthritis after the introduction of autoworld, the signs of the disease alleviated. that is, they increase mobility. they walk better innovative drug. after all you research. may be ready by 2030 a new substance, patients should be injected like diabetics. all his life, therefore, the institute has been developing a gadget for injection for him as convenient as possible, it would be the creation of a special device, and in which there would be a reservoir with a drug, such as an insulin pump or insulin pen, which can be with the patient for a long time. and at the same time, the drug does not deteriorate, does not lose

its effectiveness, retains its usual activity. here. uh, optomeric technologies allow us to assume that such a device can be created while the study is still at the start, but the institute staff has already managed to test the drug for safety. shark news yes, the pharmaceutical market for innovative drugs around the world takes years, even decades, but only in this way step step by step, scientists are working to ensure that in the future their drugs will be available to more patients. for almost a year in belgorod, a gang of strong guys was operating, bringing terror to foreigners. i remember not breaking my arm. i have a broken tooth now, a nightmare for immigrants ended immediately after the arrest of the leader of the group, david tronenko,

nicknamed carbide, told me that he adheres to the policy of national socialism. well, he talked about the action of the fight against grants. we simply have to resist all our attacks, not motivated. unfortunately, these are the slogans. they quite quickly often cling to the weak established rabid neo-nazis. and what the extremists planned to commit, that is, followed the goal of committing a mass terrorist attack with the killings of many suffering people. you will answer people. you will suffer. we took on the case and conducted our own investigation. this year they can reach almost three trillion rubles, how does otechestvennaya form compete with foreign cannery about this in the new issue?